$4.09 Million in Sales Expected for NovaBay Pharmaceuticals, Inc. (NBY) This Quarter

Equities research analysts expect NovaBay Pharmaceuticals, Inc. (NASDAQ:NBY) to report $4.09 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for NovaBay Pharmaceuticals’ earnings. The highest sales estimate is $4.51 million and the lowest is $3.67 million. NovaBay Pharmaceuticals also reported sales of $4.09 million in the same quarter last year. The firm is expected to report its next earnings report on Tuesday, November 13th.

According to Zacks, analysts expect that NovaBay Pharmaceuticals will report full year sales of $15.84 million for the current fiscal year, with estimates ranging from $14.22 million to $17.46 million. For the next fiscal year, analysts anticipate that the company will report sales of $19.55 million, with estimates ranging from $18.07 million to $21.04 million. Zacks Investment Research’s sales averages are an average based on a survey of analysts that follow NovaBay Pharmaceuticals.

NovaBay Pharmaceuticals (NASDAQ:NBY) last released its quarterly earnings results on Tuesday, August 7th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.03). The company had revenue of $2.79 million for the quarter, compared to the consensus estimate of $3.48 million.

NBY stock opened at $1.29 on Wednesday. NovaBay Pharmaceuticals has a 1 year low of $1.20 and a 1 year high of $4.75.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc, a pharmaceutical company, develops, manufactures, and markets anti-infective products for the eye care market in the United States. Its commercial products include the Neutrox family of products, Avenova for the eye care market; Aganocide compounds patented synthetic molecules with a range of spectrum of uses against bacteria, viruses, and fungi; Auriclosene Irrigation Solution for urology; CelleRx for the dermatology market; intelli-Case, a device for soft and rigid gas permeable contact lenses; and NeutroPhase for wound care.

Read More: The benefits and drawbacks of dollar cost averaging

Get a free copy of the Zacks research report on NovaBay Pharmaceuticals (NBY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply